EconomyLonza raises full-year core profit margin guidance
Swiss contract drug manufacturer Lonza raised its full-year target for core profit margin to a range of 33% to 34%. The company attributed the change to strong operational execution. It also cited contributions from growth projects that are maturing. Lonza is the world’s largest contract drug manufacturer.
R
Lonza raises full-year core profit margin guidance
Economy